Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Based on medical history, evidence of TG ≥ 500 mg/dL and ≤ 4000 mg/dL at Screening~* Fasting TG ≥ 500 mg/dL at Screening~* Willing to follow diet counseling per Investigator judgment based on local standard of care~* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~Exclusion Criteria:~* Active pancreatitis within 12 weeks prior to first dose~* Any planned bariatric surgery or similar procedures to induce weight loss from consent to end of study~* Acute coronary syndrome event within 24 weeks of first dose~* Major surgery within 12 weeks of first dose~* Planned coronary intervention (e.g., stent placement or heart bypass) or any non-cardiac major surgical procedure throughout the study~* Uncontrolled hypertension~* Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV)~* Uncontrolled hypothyroidism or hyperthyroidism~* Hemorrhagic stroke within 24 weeks of first dose~* Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)~Note: additional inclusion/exclusion criteria may apply per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARO-APOC3 10 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by subcutaneous (sc) injection
- ARO-APOC3 25 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by sc injection
- ARO-APOC3 50 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by sc injection
- Placebo, Day 1 and Week 12 (Type: PLACEBO_COMPARATOR): calculated volume to match active treatment by sc injection

Based on this trial design, predict the completion outcome and termination type (if applicable).